SCHEMBL16353073

SCHEMBL16353073

C[N+](C)(C)CCOC(=O)CC(=O)OCC[N+](C)(C)C

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.73
ADRA1A P35348 1/20 0.73
MAPT P10636 1/20 0.70
BLM P54132 1/20 0.70
CYP2C19 P33261 2/20 0.67
CHRM1 P11229 8/20 0.65
CHRM3 P20309 8/20 0.65
CHRM2 P08172 7/20 0.65
CHRM4 P08173 7/20 0.65
CHRM5 P08912 6/20 0.65
CHRNB2 P17787 4/20 0.65
CHRNA4 P43681 4/20 0.65
CHRNA7 P36544 3/20 0.65
HTR1A P08908 2/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
PGR P06401 1/20 0.65
TBXA2R P21731 1/20 0.65
CHRNB4 P30926 1/20 0.65
CHRNA3 P32297 1/20 0.65
CHRNA10 Q9GZZ6 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13346043 0.91 GAA (0.65) ADRA2AADRA1AMAPTBLMCYP2C19
SCHEMBL14045415 0.88 CHRM1 (0.64) ADRA2AADRA1AMAPTBLMCYP2C19
SCHEMBL780253 0.88 ADRA2A (0.64) ADRA2AADRA1AMAPTBLMCYP2C19
SCHEMBL28294723 0.86 ADRA2A (0.61) ADRA2AADRA1AMAPTBLMCYP2C19
Hydrochloric Acid SCHEMBL28127021 0.86 MAPT (0.65) ADRA2AADRA1AMAPTBLMCYP2C19
SCHEMBL16684872 0.84 ADRA2A (0.59) ADRA2AADRA1AMAPTBLMCYP2C19
Suxamethonium SCHEMBL41537 0.84 ADRA2A (1.00) ADRA2AADRA1AMAPTBLMCYP2C19
SCHEMBL356673 0.84 ADRA2A (0.73) ADRA2AADRA1AMAPTBLMCYP2C19
SCHEMBL25099005 0.83 ADRA2A (0.57) ADRA2AADRA1AMAPTBLMCYP2C19
Suxamethonium SCHEMBL1643328 0.82 ADRA2A (0.95) ADRA2AADRA1AMAPTBLMCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114044852-B Polymerizable eutectic solvent, conductive elastomer and preparation method of conductive elastomer 江南大学 2022-11-22 CN claimed
CN-114044852-A Polymerizable eutectic solvent, conductive elastomer and preparation method thereof 江南大学 2022-02-15 CN claimed
US-12440438-B2 Method of remotely controlling pain Novilla Pharmaceuticals, Inc. (US) 2025-10-14 US disclosed
EP-3503927-B1 TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT UNIV CALIFORNIA (US) 2025-02-19 EP disclosed
US-20240156964-A1 IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY THE ARIZONA BOARD OF REGENTS 2024-05-16 US disclosed
US-11786597-B2 Ionic liquids for transdermal drug delivery THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-10-17 US disclosed
US-20230310528-A1 DEEP EUTECTIC SOLVENT INCLUDING ONE OR MORE ACTIVE PHARMACEUTICAL INGREDIENTS DERIVED FROM MUSHROOMS OPTIMI HEALTH CORP (CA) 2023-10-05 US disclosed
US-11720018-B2 Chemically amplified resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-08-08 US disclosed
CN-109789216-B Topical skin treatment formulations based on ionic species 加利福尼亚大学董事会 2023-05-23 CN disclosed
US-20230152692-A1 CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-05-18 US disclosed
US-20230152692-A1 CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-05-18 US disclosed
US-20190192661-A1 TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-06-27 US disclosed
US-20180143532-A1 CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2018-05-24 US disclosed
US-20180086948-A1 ADHESIVE COMPOSITION, BIO-ELECTRODE, METHOD FOR MANUFACTURING A BIO-ELECTRODE, AND SALT SHIN-ETSU CHEMICAL CO., LTD. (JP) 2018-03-29 US disclosed
WO-2018044920-A1 TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-03-08 WO disclosed
US-20160263225-A1 IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY THE ARIZONA BOARD OF REGENTS 2016-09-15 US disclosed
EP-3062819-A2 IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY The Regents of The University of California (US) 2016-09-07 EP disclosed
WO-2015066647-A9 IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-09-17 WO disclosed
WO-2015066647-A2 IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-05-07 WO disclosed
US-20140377706-A1 DEVELOPER FOR PHOTOSENSITIVE RESIST MATERIAL AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2014-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190192661-A1 TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT CUTA, KRT18, SLC38A7 ADRA2A 4623/4885ADRA1A 4246/4885MAPT 2382/4885
US-20180086948-A1 ADHESIVE COMPOSITION, BIO-ELECTRODE, METHOD FOR MANUFACTURING A BIO-ELECTRODE, AND SALT SLC9A1, FN1, EPCAM ADRA2A 3217/4885ADRA1A 1359/4885MAPT 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.